Thus, MYC deactivation displays a promising therapeutic strategy in hepatoblastoma, as for many hematological and solid malignancies as well, but so far, MYC has been considered “undruggable” in the clinical setting [31]. The gene discussed is MYC; the disease is hepatoblastoma.